Mazdutide (IBI362): The Next-Generation Dual GLP-1/Glucagon Agonist for Obesity and Metabolic Health

Mazdutide (IBI362) is an emerging dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics for obesity and metabolic diseases. By combining appetite suppression with increased energy expenditure and enhanced fat oxidation, mazdutide offers significant advantages over traditional GLP-1–only therapies. Clinical studies indicate meaningful weight loss, improved glycemic control, and potential benefits for metabolic dysfunction–associated fatty liver disease. Its safety profile is generally consistent with other incretin-based drugs, with manageable gastrointestinal side effects. Ongoing clinical trials aim to confirm its efficacy and long-term metabolic benefits, positioning mazdutide as a promising next-generation therapy for obesity and related metabolic disorders.

What Is Mazdutide?

Mazdutide, also known as IBI362, is an investigational peptide drug developed by Innovent Biologics for the treatment of obesity and metabolic diseases. It belongs to a new generation of metabolic therapies known as dual agonists, specifically targeting both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. This dual-receptor approach differentiates mazdutide from earlier GLP-1–only medications and reflects a growing trend toward multi-pathway metabolic modulation.

Traditional GLP-1 receptor agonists, such as semaglutide, primarily promote weight loss by suppressing appetite, slowing gastric emptying, and improving insulin secretion. While effective, these agents may also reduce metabolic rate over time, which can limit sustained fat loss. Mazdutide was designed to address this limitation by incorporating glucagon receptor activation, which plays a key role in increasing energy expenditure and enhancing fat oxidation.

By combining GLP-1–mediated appetite control with glucagon-driven metabolic stimulation, mazdutide aims to achieve greater and more durable reductions in body weight, particularly through loss of adipose tissue rather than lean mass. This mechanism makes it especially attractive for patients with obesity complicated by metabolic disorders such as type 2 diabetes and metabolic dysfunction–associated fatty liver disease (MAFLD).

Early clinical studies have shown that mazdutide can induce significant weight loss alongside improvements in glycemic control and lipid metabolism. As a result, it is increasingly viewed as a potential competitor to other next-generation incretin-based therapies, including dual and triple hormone agonists currently in development. Although mazdutide is not yet approved for clinical use, its innovative design places it at the forefront of emerging treatments for obesity and metabolic disease.

Mechanism of Action – How Mazdutide Works

Mazdutide exerts its therapeutic effects through dual activation of the GLP-1 receptor and the glucagon receptor, a mechanism designed to address multiple drivers of obesity and metabolic dysfunction simultaneously. This dual-agonist strategy distinguishes mazdutide from traditional incretin therapies and underpins its potential for enhanced and sustained weight loss.

Activation of the GLP-1 (glucagon-like peptide-1) receptor plays a central role in appetite and glucose regulation. By stimulating GLP-1 receptors in the central nervous system, mazdutide promotes satiety and reduces caloric intake. In addition, GLP-1 receptor signaling slows gastric emptying and enhances glucose-dependent insulin secretion, leading to improved postprandial glucose control. These effects collectively support weight reduction while lowering the risk of hyperglycemia, particularly in patients with obesity-related insulin resistance or type 2 diabetes.

At the same time, mazdutide activates the glucagon receptor, which is involved in energy metabolism and lipid utilization. Unlike glucagon’s traditional association with raising blood glucose, controlled glucagon receptor activation in the context of dual agonism can increase energy expenditure, stimulate fat oxidation, and promote the mobilization of stored lipids. This mechanism helps counteract the adaptive reduction in metabolic rate that often accompanies weight loss, a common limitation of appetite-focused therapies.

The combination of GLP-1–mediated appetite suppression and glucagon-driven metabolic stimulation creates a synergistic effect. Rather than relying solely on reduced food intake, mazdutide supports weight loss through both decreased energy intake and increased energy expenditure. This dual pathway is thought to favor greater loss of adipose tissue while preserving lean body mass.

Through this integrated mechanism of action, mazdutide represents a new approach to treating obesity and related metabolic diseases, targeting not only how much patients eat, but also how efficiently their bodies burn and store energy.

Clinical Benefits and Potential Indications

Mazdutide has demonstrated promising clinical benefits across multiple metabolic parameters, positioning it as a potential next-generation therapy for obesity and related metabolic diseases. Early clinical studies indicate that its dual GLP-1 and glucagon receptor activity produces significant body weight reduction, with a favorable impact on both metabolic health and body composition.

One of the most notable benefits observed with mazdutide is clinically meaningful weight loss. Unlike therapies that rely solely on appetite suppression, mazdutide’s combined mechanism supports both reduced caloric intake and increased energy expenditure. This dual effect promotes a more metabolically efficient form of weight loss, characterized by preferential reduction in adipose tissue rather than indiscriminate loss of total body mass. Preservation of lean mass is particularly important for long-term metabolic stability, physical function, and weight maintenance.

In addition to weight reduction, mazdutide has shown beneficial effects on glycemic control. Through GLP-1–mediated insulin secretion and improved insulin sensitivity, patients may experience better regulation of fasting and postprandial glucose levels. These effects make mazdutide especially relevant for individuals with type 2 diabetes or prediabetes associated with obesity.

Mazdutide also demonstrates positive impacts on lipid metabolism and liver health. By enhancing fat oxidation and reducing lipid accumulation, it shows potential in addressing conditions such as metabolic dysfunction–associated fatty liver disease (MAFLD) and non-alcoholic steatohepatitis (NASH). Reductions in liver fat content and improvements in metabolic biomarkers suggest broader systemic benefits beyond weight loss alone.

Mazdutide vs Other Weight-Loss Drugs

Mazdutide represents a new class of dual-agonist metabolic therapies, and its unique mechanism differentiates it from existing weight-loss drugs. Comparing mazdutide to well-known therapies such as semaglutide (GLP-1 receptor agonist) and tirzepatide (GLP-1/GIP dual agonist) highlights its potential advantages and limitations.

Semaglutide, a GLP-1 receptor agonist, has been widely prescribed for obesity and type 2 diabetes. It primarily reduces body weight by suppressing appetite and slowing gastric emptying. While effective, semaglutide’s benefits are largely driven by reduced caloric intake, with modest effects on energy expenditure. This can result in adaptive reductions in metabolic rate over time, which may limit long-term fat loss.

Tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, enhances appetite control and glucose regulation. It offers robust weight-loss outcomes, but its effect on energy expenditure is less pronounced compared to glucagon-targeting therapies.

In contrast, Mazdutide’s dual GLP-1 and glucagon receptor activation not only suppresses appetite but also increases energy expenditure and promotes fat oxidation. This dual mechanism may lead to more significant and sustainable reductions in body fat, rather than weight loss primarily from lean tissue. Additionally, glucagon receptor stimulation may support liver fat reduction, potentially providing added benefits in patients with metabolic dysfunction–associated fatty liver disease (MAFLD).

Safety and tolerability remain important considerations. Mazdutide’s side-effect profile, mainly nausea, vomiting, and gastrointestinal discomfort, is similar to other incretin-based therapies. Dose titration strategies are employed to improve patient tolerability.

Overall, while semaglutide and tirzepatide remain effective options, mazdutide may offer enhanced metabolic benefits through its combination of appetite suppression, energy expenditure, and targeted fat loss, making it a promising candidate for patients with obesity complicated by metabolic disorders.

Development Status, Safety, and Future Outlook

Mazdutide is currently in clinical development and has not yet received regulatory approval for general use. Developed by Innovent Biologics, it is being evaluated in multiple phase 1 and phase 2 clinical trials for obesity, type 2 diabetes, and metabolic dysfunction–associated fatty liver disease (MAFLD). Early trial results have shown promising outcomes in both weight reduction and metabolic improvements, highlighting mazdutide’s potential as a next-generation therapy.